GYNECOLOGIC CANCERS

Additional findings from KEYNOTE-826 reveal no negative health-related quality-of-life impact when using pembrolizumab plus chemotherapy with or without bevacizumab.

Treatment with ceralasertib with and without olaparib showed promising signals of clinical activity in multiple rare gynecologic cancers, according to findings presented at the European Society for Medical Oncology Gynaecologic Cancers Congress 2023.

Anna Jo Bodurtha Smith, MD, MPH, MSc, discusses why the number of patients with gynecologic cancer that never see a gynecologic oncologist is so high.

Significant rates of homologous recombination deficiency somatic gene mutations were found in patients with uterine serous cancer, resulting in possible implications for future testing and treatment for the patient population, according to the results of a research study.

John P. Diaz, MD, explains the importance of the topics to be discusses at the Miami Cancer Institute Women’s Cancer Symposium on April 21, 2023.

John P. Diaz, MD, provides an overview of the topics to be discusses during the Miami Cancer Institute Women’s Cancer Symposium on April 21, 2023.

At the Society of Gynecologic Oncology 2023 Annual Meeting, data showed that with a median follow-up of 25.8 months, the proportion of patients on Arm A of the NRG-GY017 trial of patients with cervical cancer with 2-year disease-free survival rate was 79% vs 59% in Arm B.

Anna Jo Bodurtha Smith, MD, discusses background on her research regarding insurance-mediated disparities in gynecologic oncology.

Casey M. Cosgrove, MD, discusses research exploring precision medicine concepts for endometrial cancer treatment.

Findings from the patient-reported outcomes analysis of the phase 3 KEYNOTE-826 trial support the benefit of pembrolizumab in patients with recurrent, persistent, or metastatic cervical cancer.

In the NORA study, a 16% reduction in the risk of death was achieved with maintenance niraparib in patients with platinum-sensitive recurrent ovarian cancer.

David O’Malley, MD, discusses the background and updated results of the KEYNOTE-158 trial looking at pembrolizumab monotherapy in patients with advanced endometrial cancer.

CINtec PLUS Cytology is the only dual-stain triage test to be offered by BioReference Health LLC for patients with a high-risk human papillomavirus result.

Susana Banerjee, MBBS, PhD, discusses the significance of the long-term results of the MEDIOLA trial of patients with ovarian cancer.

During a Targeted Oncology case-based roundtable event, Paul D. DiSilvestro, MD, discussed the long-term results from the SOLO-1 trial of olaparib maintenance for patients with ovarian cancer. This is the first of 3 articles based on this event.

Robert Holloway, MD, highlights the issue of racial disparity in endometrial cancer, and the critical unmet needs for patients.

Insights into the goals of second-line therapy for patients with advanced/recurrent endometrial carcinoma, and best strategies for adverse event management.

Dr Robert Holloway explains what second-line treatment regimen he would have chosen for the patient with metastatic endometrial cancer in the presented case.

Robert Holloway, MD, review safety and efficacy data from a clinical trial investigation of lenvatinib combined with pembrolizumab for the treatment of advanced endometrial cancer.

An expert details the currently available systemic therapies for patients with MMR-proficient metastatic endometrial cancer who experienced recurrent disease after platinum-based chemotherapy.

Dr Robert Holloway describes the presentation of a typical patient with metastatic endometrial cancer, and whether all patients receive MMR testing.

Robert Holloway, MD, presents the diagnosis and treatment regimen of a 71-year-old woman with mismatch repair-proficient (pMMR) metastatic endometrial cancer.

Anna Jo Bodurtha Smith, MD, discusses her research on insurance mediated disparities in gynecologic oncology.

Susana Banerjee, MBBS, PhD, discusses the updated results of the MEDIOLA trial of patients with ovarian cancer presented at the 2022 European Society for Medical Oncology Congress.

In a phase 1 study, a peptide conjugated vaccine showed potent immunogenicity and was able to induce functional T-cell responses in almost all vaccinated patients with HPV16-positive premalignancies.